Concept by Vikas Dandekar and Muhabit ul haq

Synopsis

India’s pharmaceutical industry is globally recognized for supplying low-priced drugs and vaccines. But often that reputation is sullied when companies cut corners or ship drugs that fail stringent quality tests. India’s regulatory agencies — which function with a flawed dual central and state structure — are blamed for being corrupt and complicit in such activities. Can a regulatory overhaul change this?

Ever since the pandemic broke out, the sage advice to ‘seize the opportunity in a crisis’ has got a life of its own. It appears to have even shaken up India’s pharma and healthcare authorities to flag off an overhaul of regulations that trace their origin to 1940. However, if indeed a robust regulatory framework is to be built, seriousness of intent would be the most critical element. The health ministry has taken the first step in that

BY

Sep 21, 2021, 01:38 PM IST

• GIFT ARTICLE
• FONT SIZE

  AbcSmall

  AbcMedium

  AbcLarge

• SAVE
• PRINT
• COMMENT

Already an ET Prime Member? Sign In now

Continue reading with one of these options:

Limited Access

Free

Login to get access to some exclusive stories
& personalised newsletters

Login Now

Unlimited Access

Starting @ Rs120/month

Get access to exclusive stories, expert opinions &
in-depth stock reports

Subscribe Now

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Choose Payment Mode & Plan

–

–

–

 

Subscribe Now

(Credit card mandatory)

 

You can cancel your subscription anytime

–

–

–

 

Subscribe Now

(Pay Using Netbanking/UPI/Debit Card)

 

Netbanking, Credit & Debit Card

Subscribe with Google

₹399/month

Monthly
PLAN

Billed Amount ₹399

₹399

₹208/month

(Save 49%)

Yearly
PLAN

Billed Amount ₹2,499

15
Days Trial
+Includes DocuBay and TimesPrime Membership.

₹399

₹150/month

(Save 63%)

2-Year
PLAN

Billed Amount ₹3,599

15
Days Trial
+Includes DocuBay and TimesPrime Membership.

Subscribe NowSubscribe with

Already a Member? Sign In now

September Special Offer

Get Flat 20% Off

ON ET PRIME MEMBERSHIP

Get Offer

Why ?

• 

   

  Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

   

• 

   

  Stock analysis. Market Research. Industry Trends on 4000+ Stocks

   

• Clean experience with
  Minimal Ads
• Comment & Engage with ET Prime community
• Exclusive invites to Virtual Events with Industry Leaders
• A trusted team of Journalists & Analysts who can best filter signal from noise